Biotechnology Get all the latest news from the field of biotechnology and its many applications, including testing, treatment, and pharmaceuticals. This category includes research, clinical, and study results, as well as stories about the newest breakthroughs in the industry. Read stories about upcoming conferences and symposiums, along with releases regarding patents, legal activity, company performance, and market analysis.

Latest

Oct 24, 2020, 19:18 ET ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR Symposium

HOUSTON and VANCOUVER, BC, Oct. 24, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused...


Oct 23, 2020, 13:07 ET Neptune Wellness Solutions Inc. Closes US$35 Million Private Placement

LAVAL, QC, Oct. 23, 2020 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (TSX: NEPT) (NASDAQ: NEPT), a diversified and...


Oct 23, 2020, 12:28 ET BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a pioneer in the development of a universal flu vaccine designed to provide protection against current, ...


Oct 23, 2020, 11:27 ET PAOG Announces CRO Agreement To Advance Respiratory Cannabis Treatment Through Regulatory Approval

PAO Group, Inc. (USOTC: PAOG) today announced executing a master services agreement with a clinical research organization in the U.S. to prepare PAOG ...


Oct 23, 2020, 11:15 ET Akebia Presents Results from its PRO2TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis During Late-Breaking Session at American Society of Nephrology Kidney Week 2020 Reimagined

Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced the presentation of clinical data from its PRO2TECT global Phase 3 program that evaluated...


Oct 23, 2020, 10:21 ET Hyasynth completes key commercialization milestone for cannabinoid biosynthesis, receives $2.5 million payment

Hyasynth receives $2.5 million milestone payment following first-to-market achievement with CBD produced by fermentation MONTREAL, Oct. 23, 2020...


Oct 23, 2020, 09:15 ET Eucrates Biomedical Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering

Eucrates Biomedical Acquisition Corp. (the "Company"), a special purpose acquisition company formed for the purpose of effecting a merger, share...


Oct 23, 2020, 09:00 ET Diagnostic Testing Capabilities Improve in the Face of Global Turmoil

While biotech companies work on vaccines and possible treatments and medical device companies focus on patient monitoring solutions, many others have ...


Oct 23, 2020, 09:00 ET Front Range Biosciences Recognized as No. 1 Small Company by Denver Business Journal Fast 50 Award

Front Range Biosciences® ("FRB"), a hemp and cannabis genetics platform company, leveraging proprietary next generation breeding and Clean Stock®...


Oct 23, 2020, 08:00 ET Amyris To Host Third Quarter 2020 Financial Results Conference Call On November 5

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top...


Oct 23, 2020, 08:00 ET PharmAbcine to participate at BIO-Europe 2020

PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will participate in the 26th Annual International BIO-Europe Partnering...


Oct 23, 2020, 07:00 ET Milestone Pharmaceuticals Announces Pricing of a Public Offering of $45 Million of Common Shares and Pre-Funded Warrants

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing...


Oct 23, 2020, 05:40 ET Invitation to the Sobi Capital Markets Day 2020

Save the date for Swedish Orphan Biovitrum AB (publ) (Sobi™) Capital Markets Day on 10 December 2020. The Sobi CMD will be an opportunity for...


Oct 23, 2020, 01:15 ET BerGenBio Virtual R&D Day - 06 November 2020

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical...


Oct 22, 2020, 21:16 ET Sirnaomics Seals US$105 Million Series D Financing to Fund Development of RNAi Therapeutics for Treatment of Cancers, Fibrotic Diseases and Viral Infections

Sirnaomics Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed its...


Oct 22, 2020, 17:10 ET FDA Approves First Treatment for COVID-19

Today, the U.S. Food and Drug Administration approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age ...


Oct 22, 2020, 17:04 ET ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors; Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program

ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative immune-oncology treatments, today presents its strategy directed at...


Oct 22, 2020, 16:05 ET Dynavax to Report Third Quarter 2020 Financial Results and Host Conference Call on November 5, 2020

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report...


Oct 22, 2020, 16:00 ET Alkermes to Host Conference Call to Discuss Third Quarter 2020 Financial Results

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Thursday, Oct. 29, 2020 to...


Oct 22, 2020, 15:58 ET La FDA attribue un contrat de 1,1 M$ à CUBRC et à EpiVax pour la validation d'un nouvel outil immuno-informatique destiné aux évaluations prospectives de l'immunogénicité des médicaments peptidiques et de leurs impuretés

EpiVax, Inc. (« EpiVax ») et CUBRC, Inc. (« CUBRC ») ont annoncé aujourd'hui que le Bureau des médicaments génériques (OGD) du Centre d'évaluation et ...


Oct 22, 2020, 14:59 ET FDA vergibt Vertrag im Wert von 1,1 Mio. USD an CUBRC und EpiVax für die Validierung des neuen Immunoinformatik-Tools für prospektive Immunogenitätsbewertungen von Peptidpräparaten und deren Verunreinigungen

EpiVax, Inc. („EpiVax") und CUBRC, Inc. („CUBRC") gaben heute bekannt, dass sie einen Zweijahresvertrag über 1,1 Mio. USD vom Office of Generic Drugs ...


Oct 22, 2020, 14:13 ET Arizona Based Biotech Company Finds Preliminary Success Developing an Intranasal COVID-19 Vaccine Alternative

Sotira, a Phoenix based biotech company is proud to announce the preliminary findings of preclinical safety and efficacy studies for its...


Oct 22, 2020, 13:06 ET TrialCard Introduces New Corporate Brand Identity

TrialCard Incorporated, a pioneer in patient access, affordability, and adherence solutions for biopharmaceutical manufacturers, announced today the...


Oct 22, 2020, 10:00 ET Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company developing targeted, first-in-class medicines to improve the lives of patients with kidney...


Oct 22, 2020, 09:29 ET SOM Biotech announces poster presentation on the repurposing of Eravacycline for the treatment of SARS-CoV-2

SOM Biotech, a biopharmaceutical company specializing in the repositioning of existing drugs for the treatment of diseases with a high unmet need,...